کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9905861 | 1547307 | 2005 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of the trails, improvements in important secondary clinical outcome measures such as pain relief and quality of life measurements. In this current perspective, these two trials are summarised and discussed. It is concluded that, docetaxel every 3 weeks plus low-dose prednisone can be considered standard treatment for patients with androgen-independent disease.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 41, Issue 4, March 2005, Pages 502-507
Journal: European Journal of Cancer - Volume 41, Issue 4, March 2005, Pages 502-507
نویسندگان
Ronald de Wit,